Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported ... compared with 5.9 billion reported ...